Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 2/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.31 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17351371 | 0.95 | CES2 (0.40) | RECQLCES2CES1ACETP53 | |
| SCHEMBL3495827 | 0.93 | CES2 (0.44) | RECQLCES2CES1SMN1; SMN2ALDH1A1 | |
| SCHEMBL322380 | 0.90 | TP53 (0.36) | TP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL11714520 | 0.80 | CES2 (0.50) | RECQLCES2CES1GAASMN1; SMN2 | |
| SCHEMBL2600355 | 0.77 | — | — | |
| SCHEMBL17504886 | 0.76 | TSHR (0.40) | RECQLTP53GAASMN1; SMN2ALDH1A1 | |
| SCHEMBL4938309 | 0.75 | CES2 (0.38) | RECQLCES2CES1SMN1; SMN2ALDH1A1 | |
| SCHEMBL16215480 | 0.73 | — | — | |
| SCHEMBL16637029 | 0.73 | — | — | |
| SCHEMBL17599066 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230400766-A1 | ONIUM SALT, RESIST COMPOSITION AND PATTERN FORMING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-12-14 | — | — | US | disclosed |
| EP-1817037-B1 | TRIAZOLE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO KG (DE) | 2013-04-03 | — | — | EP | disclosed |
| US-8202868-B2 | 4-piperazinyl-pyrimidine compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | ABBOTT GMBH & CO. KG (DE) | 2012-06-19 | — | — | US | disclosed |
| US-20120095015-A1 | TRIAZOLE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2012-04-19 | — | — | US | disclosed |
| US-8101754-B2 | e.g., 2-tert-Butyl-4-{4-[3-(4-methyl-5-methyl-4H-[1,2,4]triazol-3-ylsulfanyl)-propyl]-piperazin-1-yl}-6-(1-methylcyclopropyl)-pyrimidine hydrochloride; central nervous system disorders; schizophrenia; antidepressant, anxiolytic agent, cognition activator; Parkinson's and Alzheimer's diseases | ABBOTT GMBH & CO. KG (DE) | 2012-01-24 | — | — | US | disclosed |
| EP-1778684-B1 | 4-PIPERAZINYL-PYRIMIDINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D<sb>3</sb> RECEPTOR | ABBOTT GMBH & CO KG (DE) | 2009-12-16 | — | — | EP | disclosed |
| US-20090264437-A1 | 4-Piperazinyl-Pyrimidine Compounds Suitable for Treating Disorders that Respond to Modulation of the Dopamine D3 Receptor | ABBOTT GMBH & CO. KG (DE) | 2009-10-22 | — | — | US | disclosed |
| US-20080171751-A1 | Triazole Compounds Suitable for Treating Disorders that Respond to Modulation of the Dopamine D3 Receptor | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2008-07-17 | — | — | US | disclosed |
| EP-1778684-A1 | 4-PIPERAZINYL-PYRIMIDINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D&lt;sb&gt;3&lt;/sb&gt; RECEPTOR | Abbott GmbH & Co. KG (DE) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006015842-A1 | 4-PIPERAZINYL-PYRIMIDINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2006-02-16 | — | — | WO | disclosed |
| US-5583015-A | CULTURING MUTANT STRAIN OF STREPTOMYCES AVERMITILIS LACKING BRANCHED CHAIN AMINO ACID TRANSAMINASE AND/OR 2-OXO ACID DEHYDROGENASE ACTIVITY UNDER AEROBIC CONDITIONS IN AQUEOUS NUTRIENT MEDIUM CONTAINING SPECIFIED ACID OR PRECURSOR | PFIZER INC. (US) | 1996-12-10 | — | — | US | disclosed |
| US-5525506-A | Process for production of avermectins and cultures therefor | PFIZER INC. (US) | 1996-06-11 | — | — | US | disclosed |
| US-5238848-A | Cultures for production of avermectins | PFIZER INC (US) | 1993-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264437-A1 | 4-Piperazinyl-Pyrimidine Compounds Suitable for Treating Disorders that Respond to Modulation of the Dopamine D3 Receptor | ADRA1D, ADRA1A, ADRA2A | RECQL 424/4885CES2 2380/4885CES1 3520/4885 |
| US-20120095015-A1 | TRIAZOLE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ADRB3, DRD3, ADORA3 | RECQL 3362/4885CES2 1017/4885CES1 1287/4885 |
| US-20080171751-A1 | Triazole Compounds Suitable for Treating Disorders that Respond to Modulation of the Dopamine D3 Receptor | ADRB3, DRD3, ADORA3 | RECQL 3235/4885CES2 976/4885CES1 1146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.